| 000 | 01829 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513194136.0 | ||
| 264 | 0 | _c19991210 | |
| 008 | 199912s 0 0 eng d | ||
| 022 | _a0027-8424 | ||
| 024 | 7 |
_a10.1073/pnas.96.22.12855 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBourrié, B | |
| 245 | 0 | 0 |
_aThe neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment. _h[electronic resource] |
| 260 |
_bProceedings of the National Academy of Sciences of the United States of America _cOct 1999 |
||
| 300 |
_a12855-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBlood-Brain Barrier |
| 650 | 0 | 4 |
_aCytokines _xmetabolism |
| 650 | 0 | 4 |
_aEncephalomyelitis, Autoimmune, Experimental _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aLipopolysaccharides _xadministration & dosage |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 |
_aNaphthalenes _xadministration & dosage |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Inbred Lew |
| 650 | 0 | 4 |
_aTh1 Cells _ximmunology |
| 650 | 0 | 4 |
_aTh2 Cells _ximmunology |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xbiosynthesis |
| 700 | 1 | _aBribes, E | |
| 700 | 1 | _aEsclangon, M | |
| 700 | 1 | _aGarcia, L | |
| 700 | 1 | _aMarchand, J | |
| 700 | 1 | _aThomas, C | |
| 700 | 1 | _aMaffrand, J P | |
| 700 | 1 | _aCasellas, P | |
| 773 | 0 |
_tProceedings of the National Academy of Sciences of the United States of America _gvol. 96 _gno. 22 _gp. 12855-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1073/pnas.96.22.12855 _zAvailable from publisher's website |
| 999 |
_c10492912 _d10492912 |
||